about
The safety of long-acting ß2-agonists in the treatment of stable chronic obstructive pulmonary diseaseBeta2-adrenoceptor signaling is required for the development of an asthma phenotype in a murine modelA review of the most common patient-reported outcomes in COPD--revisiting current knowledge and estimating future challengesThe effects of cigarette smoke on airway inflammation in asthma and COPD: therapeutic implicationsBronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthmaLebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies.Blocking KV1.3 channels inhibits Th2 lymphocyte function and treats a rat model of asthmaBurden of COPD in a government health care system: a retrospective observational study using data from the US Veterans Affairs population.Development of the Lung Function Questionnaire (LFQ) to identify airflow obstructionAnxiety and depression in COPD: current understanding, unanswered questions, and research needsClinical implications of the intrinsic efficacy of beta-adrenoceptor drugs in asthma: full, partial and inverse agonism.Chronic obstructive pulmonary disease exacerbations: latest evidence and clinical implications.Lebrikizumab treatment in adults with asthma.Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial.One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD.The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial.Beta-agonist intrinsic efficacy: measurement and clinical significance.Prevalence of airway obstruction assessed by lung function questionnairePulmonary-renal syndromes in the intensive care unit.Measuring the impact of a live, case-based, multiformat, interactive continuing medical education program on improving clinician knowledge and competency in evidence-based COPD careRacial differences in CT phenotypes in COPD.Comorbidities of COPD have a major impact on clinical outcomes, particularly in African Americans.Asthma in the elderly: Current understanding and future research needs--a report of a National Institute on Aging (NIA) workshop.Resting energy expenditure and protein turnover are increased in patients with severe chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes.Racial differences in quality of life in patients with COPD.Glucose and pyruvate metabolism in severe chronic obstructive pulmonary disease.Anti-inflammatory activities of beta2-agonists.Acute asthma in pregnancy.Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease.Common Genetic Polymorphisms Influence Blood Biomarker Measurements in COPD.Treatments for COPD.Examining fatigue in COPD: development, validity and reliability of a modified version of FACIT-F scale.Influenza vaccine in patients with asthma.The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot studyRevisiting asthma control: how should it best be defined?Effect of a primary care continuing education program on clinical practice of chronic obstructive pulmonary disease: translating theory into practice.Optimizing safety of COPD treatments: role of the nurse practitioner.One hundred years of chronic obstructive pulmonary disease (COPD).Update on the pharmacologic therapy for chronic obstructive pulmonary disease.
P50
Q22305858-FA2E97B7-19C6-4AB1-B801-B9C73AC140A0Q24646260-81F9F47E-8900-40CB-92BB-39F8DEB61D01Q26992071-092FFC7B-0548-42FC-8999-8771030E5FBDQ27004651-D945DFBC-AEF0-4A96-9516-F1D6438B5F3AQ30409292-E9D859D6-D2D7-469D-A558-50C7D752D909Q30957004-7B719005-DE30-454E-A1FC-6AAED1C446EDQ33556185-84FAE62A-534D-4524-8D8B-573BB10D0984Q33575949-14088C54-0457-4DC8-A786-9F33977924A2Q33755806-CD3E9378-1126-4513-8A71-F334D3F5001EQ33769925-63180CE8-C007-4AF9-A9C1-CFA84811B645Q33792699-82144236-63C1-402D-9E9D-6856C3DDBACDQ34039712-CAF82C24-7697-46C4-9F8D-B969C125DD95Q34205683-722684FF-B0D2-4395-B9B0-DDA2FD9E0F65Q34521884-A72A7CDE-04D1-42C3-953F-9D71C5716FA0Q34609913-68219D02-1F18-4093-A344-A6127952D006Q34635098-C62E3C2F-B7E9-47FD-BCB0-7FF88E43C85DQ34642515-0129973F-354D-4176-880A-2DBED9DF117BQ34887841-1D29363D-9631-4576-AE98-B74341A941EEQ34990088-7A37BCE9-2321-44BC-9069-9974C305C68BQ35056998-62E892EF-97ED-4F35-A286-7D662DE966C4Q35064411-ED7814BF-A5C4-49AB-BAE3-78DF798D0F32Q35087187-0B0660B3-E588-4312-906C-C8C819306E62Q35190242-E57151EF-9EE5-40C4-8EAB-BA0AB3B2758FQ35223742-12B37588-BFD6-48C0-8383-636607F382D7Q35249531-2B50864E-B7CA-4971-B869-51ED18CB34C0Q35497243-887E0B00-D69E-41E0-8808-026E9EB5D474Q35790167-2BC00420-E99F-4F46-A4AD-29D4E9F3259BQ35892620-44E4EF9A-0C4B-4E05-B36F-E4308D1E0FD7Q35896839-38B616A2-E35C-4E19-B9D3-79B8BA0C8341Q36034103-69AA21FB-3607-4394-B670-B1FC923F2EE2Q36105702-650E1F36-5B23-43F3-B4FE-1D732002F560Q36292487-186E7A4C-5D95-41DE-8F22-C7F828F6C5EEQ36377017-11E27DA1-863A-4755-AFF9-75DB28593C37Q36383823-372AD40D-7666-4963-9704-6F9E8D96685CQ36477727-27D94AD0-18CA-4E6E-9E9E-081F3D04239EQ36510442-B3271517-379E-47F3-90C6-53C121D9E73AQ36513117-12FC07F5-BE6E-4D96-8570-42FDBDA85956Q36642198-EEFEA299-C3CB-48E1-A8E5-3731BC1F11A3Q36760829-883B41E4-20F4-48AC-A35C-3FDF8CFE0FF6Q36919354-7AC1654C-6F7C-444A-AFBC-CF87B6C7ED04
P50
description
associate professor at Baylor College of Medicine
@en
onderzoeker
@nl
name
Nicola A Hanania
@ast
Nicola A Hanania
@en
Nicola A Hanania
@nl
type
label
Nicola A Hanania
@ast
Nicola A Hanania
@en
Nicola A Hanania
@nl
altLabel
Nicola Alexander Hanania, M.D., M.S.
@en
Nicola Hanania
@en
prefLabel
Nicola A Hanania
@ast
Nicola A Hanania
@en
Nicola A Hanania
@nl
P214
P244
P1053
C-5875-2016
P106
P21
P214
P244
n2011181110
P31
P3829
P496
0000-0003-3087-9530
P734
P735
P7859
lccn-n2011181110